Subsequent Event (Additional Information) (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Aug. 08, 2025 |
Jul. 31, 2025 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
|
| Subsequent Event [Line Items] | ||||||
| Clinical research services expenses | $ 5,270,967 | $ 3,075,830 | $ 15,784,546 | $ 5,827,109 | ||
| Subsequent Event [Member] | ||||||
| Subsequent Event [Line Items] | ||||||
| Clinical supply agreement amount | $ 6,500,000 | |||||
| Clinical research services expenses | $ 22,300,000 | |||||
| X | ||||||||||
- Definition Clinical Supply Agreement Amount No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|